alpha-aminopyridine has been researched along with Head and Neck Neoplasms in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 14 (73.68) | 24.3611 |
| 2020's | 5 (26.32) | 2.80 |
| Authors | Studies |
|---|---|
| Arshad, S; Brisson, RJ; Dekker, A; DeSouza, JA; Kochanny, S; Saloura, V; Seiwert, TY; Vokes, EE | 1 |
| Caignet, X; El Baroudi, M; Machiels, JP; Pyr Dit Ruys, S; Roger, PP; Schmitz, S; van Caloen, G; Vertommen, D | 1 |
| Byeon, HK; Cho, BC; Choi, JW; Hong, MH; Jung, I; Kang, HN; Kim, DH; Kim, HR; Kim, J; Kim, JH; Koh, YW; Lee, H; Lim, SM; Paik, S; Park, AY; Park, YM; Pyo, KH; Shin, EJ; Yoon, SO; Yun, MR | 1 |
| Ahn, MJ; Cho, BC; Choi, EC; Choi, JW; Hong, MH; Ju, KY; Jung, DM; Kang, HN; Kim, HR; Kim, HS; Kim, J; Kim, KR; Kim, SH; Kim, TM; Koh, YW; Paik, S; Pyo, KH; Shim, HS; Sun, JM; Yoo, J; Yoon, SO; Yun, MR | 1 |
| Chera, B; Lenze, N; Sheth, S | 1 |
| Chen, JH; Chuang, FC; Hwang, TZ; Su, YC; Wang, CC; Yeh, SA | 1 |
| Cho, BC; Choi, HM; Hong, MH; Joo, HS; Kang, HN; Kim, DH; Kim, HR; Lee, Y; Yoon, SO; Yun, MR | 1 |
| Huang, CI; Hung, SK; Lin, PM; Su, YC; Tai, TS; Wang, CC; Wu, CF | 1 |
| Alarcon, S; Collins, J; Doroshow, JH; Kinders, RJ; Kummar, S; Lee, MJ; Park, SR; Pfister, T; Piekarz, R; Speranza, G; Steinberg, SM; Trepel, JB; Wang, L; Wright, JJ | 1 |
| Ando, Y; Doi, T; Inada-Inoue, M; Kakizume, T; Mitsuma, A; Ohtsu, A; Quadt, C; Robson, M; Sato, M; Suenaga, N; Yoshino, T | 1 |
| Lattanzio, L; Lo Nigro, C; Merlano, M; Milano, G; Monteverde, M; Russi, E; Tonissi, F; Vivenza, D | 1 |
| Ahn, JS; Ahn, MJ; Bae, YH; Koh, J; Ku, BM; Lee, SH; Park, K; Sun, JM; Yi, SY | 1 |
| Barker, HE; Bhide, S; Harrington, KJ; McLaughlin, M; Newbold, KL; Nutting, CM; Patel, R; Schick, U; Zaidi, S | 1 |
| Bozec, A; Chamorey, E; Ebran, N; Gautier, M; Marcie, S; Milano, G; Penault-Llorca, F; Radosevic-Robin, N; Yahia, HB | 1 |
| Chau, NG; Haddad, RI; Tishler, RB | 1 |
| Amin, AR; Anisuzzaman, AS; Chen, Z; Chen, ZG; Haque, A; Rahman, MA; Shin, DM; Wang, D; Zhang, C | 1 |
| Barker, HE; Dillon, MT; Hafsi, H; Harrington, K; Khoo, V; Kyula, J; McLaughlin, M; Patel, R; Schick, U; Thompson, A; Zaidi, S | 1 |
| Aimone, P; Alyasova, A; Barone, C; Chakravartty, A; Chol, M; Dechaphunkul, A; Erfán, J; Faivre, S; Hirawat, S; Karpenko, A; Kasper, S; Kim, SB; Kiss, LA; Li, SH; Licitra, L; Lin, JC; Mesía, R; Nagarkar, R; Ochsenreither, S; Remenár, É; Soulières, D; Tamás, L; Turri, S | 1 |
| Fiedler, W; Schultze, A | 1 |
2 review(s) available for alpha-aminopyridine and Head and Neck Neoplasms
| Article | Year |
|---|---|
An evaluation of buparlisib for the treatment of head and neck squamous cell carcinoma.
Topics: Aminopyridines; Class I Phosphatidylinositol 3-Kinases; Head and Neck Neoplasms; Humans; Maximum Tolerated Dose; Morpholines; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Squamous Cell Carcinoma of Head and Neck | 2021 |
Clinical importance and potential use of small molecule inhibitors of focal adhesion kinase.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Clinical Trials, Phase I as Topic; Focal Adhesion Kinase 2; Focal Adhesion Protein-Tyrosine Kinases; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Hydroxamic Acids; Indoles; Male; Molecular Targeted Therapy; Neoplasms; Neovascularization, Pathologic; Pancreatic Neoplasms; Prostatic Neoplasms; Protein Kinase Inhibitors; Signal Transduction; Sulfonamides | 2011 |
5 trial(s) available for alpha-aminopyridine and Head and Neck Neoplasms
| Article | Year |
|---|---|
A pilot study of the pan-class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer.
Topics: Aged; Aminopyridines; Antineoplastic Agents, Immunological; Cetuximab; Drug Therapy, Combination; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Morpholines; Neoplasm Recurrence, Local; Pilot Projects; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2019 |
Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Checkpoints; Cell Survival; Cetuximab; DNA Copy Number Variations; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Head and Neck Neoplasms; Humans; Male; Mice; Mice, Nude; Mice, SCID; Middle Aged; Morpholines; Mutation; Neoplasm Transplantation; Progression-Free Survival; Reproducibility of Results; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome; Up-Regulation; Whole Genome Sequencing | 2020 |
A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Aged, 80 and over; Aminopyridines; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cohort Studies; Colorectal Neoplasms; Endothelial Cells; Female; Head and Neck Neoplasms; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Morpholines; Neoplasms; Oxazines; Pheochromocytoma; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Thyroid Neoplasms | 2013 |
Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Agents; Area Under Curve; Carcinoma, Squamous Cell; Colorectal Neoplasms; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Japan; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Treatment Outcome; Young Adult | 2014 |
Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Double-Blind Method; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; International Agencies; Male; Middle Aged; Morpholines; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Platinum; Prognosis; Survival Rate | 2017 |
12 other study(ies) available for alpha-aminopyridine and Head and Neck Neoplasms
| Article | Year |
|---|---|
Preclinical Activity of Ribociclib in Squamous Cell Carcinoma of the Head and Neck.
Topics: Aminopyridines; Animals; Apoptosis; Biomarkers, Tumor; Cell Cycle; Cell Movement; Cell Proliferation; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Epithelial-Mesenchymal Transition; Female; Forkhead Box Protein M1; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Purines; Retinoblastoma Protein; Squamous Cell Carcinoma of Head and Neck; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer.
Topics: Afatinib; Aminopyridines; Animals; Biopsy; Carcinoma, Squamous Cell; Gene Amplification; Gene Regulatory Networks; Genetic Variation; Head and Neck Neoplasms; High-Throughput Nucleotide Sequencing; Humans; Methotrexate; Mice; Morpholines; Papillomavirus Infections; Patient-Specific Modeling; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
PI3k inhibitors (BKM120 and BYL719) as radiosensitizers for head and neck squamous cell carcinoma during radiotherapy.
Topics: Aminopyridines; Carcinoma, Squamous Cell; Cell Line, Tumor; Head and Neck Neoplasms; Humans; Morpholines; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Radiation-Sensitizing Agents; Thiazoles | 2021 |
ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
Topics: Aminopyridines; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Autocrine Communication; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Female; Head and Neck Neoplasms; Humans; Interleukin-6; MAP Kinase Signaling System; Mice; Mice, Inbred NOD; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Receptors, Interleukin-6; RNA, Small Interfering; Squamous Cell Carcinoma of Head and Neck; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2018 |
CDK4/6 Inhibitor LEE011 Is a Potential Radiation-sensitizer in Head and Neck Squamous Cell Carcinoma: An
Topics: Aminopyridines; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Head and Neck Neoplasms; Humans; Mouth Neoplasms; Phosphorylation; Purines; Radiation-Sensitizing Agents; Retinoblastoma Binding Proteins; Squamous Cell Carcinoma of Head and Neck; Ubiquitin-Protein Ligases | 2019 |
Treatment effect of buparlisib, cetuximab and irradiation in wild-type or PI3KCA-mutated head and neck cancer cell lines.
Topics: Aminopyridines; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cetuximab; Chemoradiotherapy; DNA Repair; Drug Resistance, Neoplasm; ErbB Receptors; Head and Neck Neoplasms; Humans; Mechanistic Target of Rapamycin Complex 2; Morpholines; Multiprotein Complexes; Phosphatidylinositol 3-Kinases; TOR Serine-Threonine Kinases | 2015 |
The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma.
Topics: Aminopyridines; Animals; Apoptosis; Benzimidazoles; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Cycle; Cell Proliferation; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Therapy, Combination; Everolimus; Female; Head and Neck Neoplasms; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; TOR Serine-Threonine Kinases; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
CHK1 Inhibition Radiosensitizes Head and Neck Cancers to Paclitaxel-Based Chemoradiotherapy.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Chemoradiotherapy; Combined Modality Therapy; Disease Models, Animal; Female; Head and Neck Neoplasms; Humans; Mice; Mitosis; Neoplastic Stem Cells; Paclitaxel; Protein Kinase Inhibitors; Pyrimidines; Radiation Tolerance; Radiation-Sensitizing Agents; Radiation, Ionizing; Xenograft Model Antitumor Assays | 2016 |
Combination of phosphotidylinositol-3-kinase targeting with cetuximab and irradiation: A preclinical study on an orthotopic xenograft model of head and neck cancer.
Topics: Aminopyridines; Animals; Antineoplastic Agents, Immunological; Carcinoma, Squamous Cell; Cetuximab; Combined Modality Therapy; Disease Models, Animal; Female; Head and Neck Neoplasms; Mice; Mice, Nude; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays | 2017 |
Highlights in Head and Neck Cancer.
Topics: Aminopyridines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemoradiotherapy; Clinical Trials as Topic; Enzyme Inhibitors; Head and Neck Neoplasms; Humans; Molecular Targeted Therapy; Morpholines; Nasopharyngeal Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Programmed Cell Death 1 Receptor; Squamous Cell Carcinoma of Head and Neck | 2017 |
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Cytoprotection; Drug Resistance, Neoplasm; Drug Synergism; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Mice; Morpholines; Proto-Oncogene Proteins c-akt; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2017 |
An orally bioavailable Chk1 inhibitor, CCT244747, sensitizes bladder and head and neck cancer cell lines to radiation.
Topics: Administration, Oral; Aminopyridines; Animals; Cell Line, Tumor; Checkpoint Kinase 1; Female; G2 Phase Cell Cycle Checkpoints; Head and Neck Neoplasms; Histones; Humans; Mice; Pyrimidines; Radiation-Sensitizing Agents; Urinary Bladder Neoplasms | 2017 |